Effects of dapagliflozin on major adverse kidney and cardiovascular events in patients with diabetic and non-diabetic chronic kidney disease: a prespecified analysis from the DAPA-CKD trial

Supporters

Support the authors with ResearchCoin

Tip RSC

Journal

The Lancet Diabetes & Endocrinology

Topics

Medicine

Pathology

Internal Medicine

Endocrinology

Surgery

Show all topics

DOI

10.1016/s2213-8587(20)30369-7

Other Formats

PDF